Martin Rhee

Dr. Martin Rhee is currently an Executive Director in Clinical Development in Virology at Gilead Sciences, leading the clinical development of lenacapavir, the first-in-class long acting HIV capsid inhibitor. Over the past decade, Dr. Rhee made significant contributions in bringing many of Gilead’s novel HIV medicines to people with HIV. Dr. Rhee received a medical degree from Seoul National University in Korea and completed his residency in internal medicine at Dartmouth Hitchcock Medical Center and fellowship in infectious disease at Tufts Medical Center.